© 2020 MJH Life Sciences and HCPLive. All rights reserved.
July 31, 2020
The FDA will be working over the next few months to ensure tralokinumab is efficient for atopic dermatitis.
An expert explains differences between tralokinumab and other popular agents for atopic dermatitis.
July 28, 2020
The data from the phase 3 AD Up trial add to existing knowledge of the efficacy and safety of upadacitinib for patients with atopic dermatitis.
July 24, 2020
Kim Kjøller, MD, breaks down the findings from ECZTRA1, 2, and 3.
Kim Kjøller, MD, discusses how tralokinumab can be used for the treatment of atopic dermatitis.
July 21, 2020
Upadacitinib 15 mg and 30 mg outperformed placebo in Measure Up 2, the second part of a phase 3 study on the monotherapy.
July 09, 2020
Subcutaneous injections of nemolizumab in addition to topical agents result in a greater reduction in pruritus than placebo plus topical agents.
June 19, 2020
The FDA is allowing the pen to be used for the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP) patients at least 12 years old.
May 26, 2020
The newest indication for the add-on biologic grants it use in children aged 6-11 years old with moderate to severe, uncontrolled atopic dermatitis.
May 03, 2020
A systematic review and meta-analysis show the systemic therapies, as well as a couple investigational biologics, may be superior.